Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 2/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.60 |
| ▸ | CTSS | P25774 | 1/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.59 |
| ▸ | TACR1 | P25103 | 2/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.57 |
| ▸ | ECE1 | P42892 | 2/20 | 0.57 |
| ▸ | REN | P00797 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9830575 | 0.96 | CAPN1 (0.62) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL1436898 | 0.96 | CAPN1 (0.62) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL4402534 | 0.93 | CAPN1 (0.59) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL4402523 | 0.93 | CAPN1 (0.59) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL29576951 | 0.92 | MME (0.63) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL6379430 | 0.90 | CAPN1 (0.65) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL16462972 | 0.90 | PPARA (0.56) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL31607495 | 0.90 | CTSK (0.60) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL16462974 | 0.90 | PPARA (0.56) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL9359914 | 0.89 | CTSK (0.60) | CTSKCTSLCTSBCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589066-B2 | Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-09-15 | — | — | US | claimed |
| EP-1863513-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | The University of North Carolina at Chapel Hill (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-10-26 | — | — | US | claimed |
| WO-2006099261-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-21 | — | — | WO | claimed |
| US-20160000912-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR | ROCHE GLYCART AG (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20150353640-A1 | ANTIBODY FORMULATION | HOFFMANN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2205318-B1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR | ROCHE GLYCART AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2234600-B1 | ANTIBODY FORMULATION | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20120219549-A1 | Combination therapy of a type II anti-CD20 antibody with a proteasome inhibitor | Hoffman-La Roche. Inc. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20110200598-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR | HOFFMAN-LA ROCHE, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2234600-A1 | ANTIBODY FORMULATION | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2205318-A2 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR | Roche Glycart AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-7589066-B2 | Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2009080541-A1 | ANTIBODY FORMULATION | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090162352-A1 | ANTIBODY FORMULATION | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090110688-A1 | COMBINATION THERAPY OF TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR | ROCHE GLYCART AG (CH) | 2009-04-30 | — | — | US | disclosed |
| WO-2009053038-A2 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| EP-1863513-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | The University of North Carolina at Chapel Hill (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-10-26 | — | — | US | disclosed |
| WO-2006099261-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | SERPINB1, DNPEP, PSMB2 | CTSK 80/4885CTSL 116/4885CTSB 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.